Showing 5051-5060 of 9116 results for "".
- Sirnaomics Doses First Patient in Phase 2b Study of STP705 for Treatment of Squamous Cell Skin Cancerhttps://practicaldermatology.com/news/sirnaomics-doses-first-patient-in-phase-2b-study-of-stp705-for-treatment-of-squamous-cell-skin-cancer/2460857/Sirnaomics, Inc. dosed the first patient in a Phase 2b study of the company's drug candidate, STP705, for the trea
- European Commission Approves Libtayo as First Immunotherapy for Patients with Advanced BCChttps://practicaldermatology.com/news/european-commission-approves-libtayo-as-first-immunotherapy-for-patients-with-advanced-bcc/2460851/The PD-1 inhibitor Libtayo® (cemiplimab, Regeneron/Sanofi) is approved by the European Commission to treat adults with locally advanced or metastatic basal cell carcinoma (BCC) who have progressed on or are intolerant to a hedgehog pathway inhibitor (HHI). Libtayo is now approved for thr
- Golden State Dermatology Adds Concord Practicehttps://practicaldermatology.com/news/golden-state-dermatology-adds-concord-practice/2460850/Curtis A. Raskin, MD, PhD, FAAD and his team are now part of Golden State Dermatology. The clinic in Downtown Concord adds to the eight new locations Golden State added in 2020, after adding eight in 2019. Dr. Raskin received his medical degree and PhD in molecular biology from State Un
- Foods High in Sugar and Fat Disrupt the Gut Microbiome and Trigger Psoriasis Flareshttps://practicaldermatology.com/news/foods-high-in-sugar-and-fat-disrupt-the-gut-microbiome-and-trigger-psoriasis-flares/2460846/Diets rich in sugar and fat may lead to an imbalance in the gut’s microbial culture and contribute to inflammatory skin diseases such as psoriasis, according to a new study in the Journal o
- DermTech Fills Three Leadership Postshttps://practicaldermatology.com/news/dermtech-fills-three-leadership-posts/2460843/With three new appointments, DermTech has filled key leadership roles at the company. Loren Clarke, MD is now Chief Medical Officer, Ray Bassi is Vice President, Sales, and Patrick Johnson is Vice President, Information Technology and Digital Systems. Dr. Clarke, a board-ce
- Research Brief: Personalized Bacteriotherapy May Improve Skin Microbiome and Symptoms in ADhttps://practicaldermatology.com/news/research-brief-personalized-bacteriotherapy-may-improve-skin-microbiome-and-symptoms-in-ad/2460841/Bacteriotherapy with an autologous strain of bacteria may safely improve S. aureus colonization in the microbiome of patients with atopic dermatitis (AD) and improve disease severity, a
- Nutrafol Launches Postpartum Formulahttps://practicaldermatology.com/news/nutrafol-launches-postpartum-formula/2460838/The first-of-its-kind postpartum hair nutraceutical is now available from Nutrafol. Nutrafol Postpartum was developed with an OB/GYN to target the root causes of excess hair shedding and thinning post-pregnancy. It is intended to help the body recover from the physical stress of childbirth,
- Water's Edge Partners with Goodman Dermatologyhttps://practicaldermatology.com/news/waters-edge-partners-with-goodman-dermatology/2460837/Water’s Edge Dermatology has partnered with Goodman Dermatology, P.C., a general and cosmetic dermatology practice in Atlanta. Water’s Edge Dermatology recently merged with Riverchase Dermatology (collectively, “WED/RCD”) and is a leading provider of compreh
- Dermatologist Named as AMA President-Electhttps://practicaldermatology.com/news/dermatologist-named-as-ama-president-elect/2460835/Jack Resneck Jr, MD, a dermatologist from the San Francisco Bay Area, is the new president-elect of the American Medical Association (AMA). Following a year-long term as president-elect, Dr. Resneck will assume the office of AMA president in June 2022. “It is truly an honor t
- CellFX from Pulse Biosciences Cleared in Canadahttps://practicaldermatology.com/news/cellfx-from-pulse-biosciences-cleared-in-canada/2460833/The CellFX® System from Pulse Biosciences is now approved via a Medical Device License from Health Canada for use in dermatological procedures requiring ablation and resurfacing of the skin for the reduction, removal, and/or clearance of cellular-based benign lesions. Puls